Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 for drug discovery and mechanism of action (MOA) research

Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 211, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc.,[1] the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.

Alefacept is a recombinant Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Alefacept is used to treat moderate to severe plaque psoriasis. It Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-729-1mg	1mg	3090
GMP-Bios-INN-729-10mg	10mg	Inquiry
GMP-Bios-INN-729-100mg	100mg	Inquiry
GMP-Bios-INN-729-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Alefacept Biosimilar, Fusion Protein targeting CD2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LFA-2/SRBC/T11
INN Name	Alefacept
Target	CD2
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [CD58 (LFA3, lymphocyte function associated antigen 3)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [CD58 (LFA3, lymphocyte function associated antigen 3)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Astellas Pharma US, Inc. (Northbrook IL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0